NCT06015217CompletedPhase 4
An Open-label Study to Assess Efficacy and Safety of a Healing Ointment When Used on Infants With Mild-to-moderate Diaper Rash
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Galderma R&D
- Enrollment
- 26
- Locations
- 2
- Primary Endpoint
- Product Efficacy
Study Overview
Brief Summary
The goal of this clinical trial is to assess the efficacy and safety of a Healing Ointment in infants 2-24 months with mild to moderate diaper rash. The main question it aims to answer is:
• does a Healing Ointment improve skin texture and smoothness in infants with mild to moderate diaper dermatitis? Participants will use a Healing Ointment on the diaper area with every diaper change, have the Investigator perform efficacy and tolerability assessments, and complete questionnaires regarding subject satisfaction.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 2 Months to 24 Months (Child)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •The subjects must meet all the following criteria to be eligible for the study:
- •Infant subjects aged 2 months to 24 months
- •Females and males
- •All Fitzpatrick skin types I-VI
- •All races and ethnicities
- •Subject diagnosed with mild-to-moderate diaper rash
- •Subject with healthy immune systems
- •Willing to be photographed at each visit (optional)
- •Willing to abstain from use of any other topical diaper rash treatments (ointments, moisturizers, emollients, creams, and wipes) other than the assigned test product and skincare products that have been routinely used on the diaper area during the duration of the study
- •Willing to continue using regular brands of face/body cleanser and not to begin use of any new skincare products other than the test product for the duration of the study
- •Parent/legal guardian/legal guardians must be at least 18 years old and are willing and able to present proof of legal guardianship
- •Parent/legal guardian/legal guardian with ability to read, understand and give consent for participation in the study
- •Parent/legal guardians/legal guardians willing to sign a photography release form
- •Parent/legal guardian/guardian must agree to adhere to the procedures and requirements of the study and to report to the site on the day(s) and at the time(s) scheduled for the assessments
Exclusion Criteria
- •The presence of any of the following exclusion criteria excluded a subject from enrollment in the study:
- •Subject diagnosed with severe diaper rash
- •History of allergy or hypersensitivity to any ingredient of the test product
- •Presence of any disease or lesions near or on the area to be treated, e.g.,
- •Inflammation, active, or chronic infection in or near the treatment area
- •Psoriasis, eczema, rosacea, atopic dermatitis, herpes zoster/herpes simplex, and acanthosis
- •Scars or deformities
- •History of coexisting bacterial infections or medical conditions with uncontrolled gastrointestinal diseases and/or bowel movements
- •History of severe elastosis and/or excessive sun exposure that, in the opinion of the Investigator, could have affected the outcome of the study
- •Planning on having surgeries and/or invasive medical procedures during the course of the study
- •Treatment with chemotherapy, immunosuppressive agents, inhaled corticosteroids, immunomodulatory therapy (e.g., monoclonal antibodies or antiviral treatment for human immunodeficiency virus or hepatitis C)
- •Current use of topical corticosteroids, topical prescription, or oral antibiotics in the treatment area, or use within last 2 weeks
- •Current use of over-the counter topical medications for diaper rash
- •History of cancer or previous radiation near or on the treatment area
- •Human immunodeficiency virus positive or active hepatitis
- •Presence of dermal markings on or near the treatment area that, in the opinion of the Investigator, will interfere with the clinical assessments
- •Any medical condition that, in the opinion of the Investigator, would make the subject unsuitable for inclusion (e.g., a chronic or relapsing, disease that may interfere with the outcome of the study)
- •Other condition preventing the subject from entering the study in the Investigator's opinion, (e.g., subjects failing baseline assessments, subjects not likely to avoid other cosmetic treatments in the treatment area, subjects anticipated to be unavailable or incapable of understanding the study assessments or having unrealistic expectations of the treatment result).
- •Study site personnel, close relatives of the study site personnel (e.g., parent/legal guardians, children, siblings, or spouse), or employees and close relatives of employees at the Sponsor company.
- •Participation in any interventional clinical study within 30 days of screening
Arms & Interventions
Treatment Group
Experimental
All subjects have mild to moderate diaper dermatitis and are given "Cetaphil Healing Ointment" to use with every diaper change.
Intervention: "Cetaphil Healing Ointment" (Drug)
Outcomes
Primary Outcomes
Product Efficacy
Time Frame: Week 1, Week 3
Product efficacy will be measured by Investigator's evaluation of skin's tactile smoothness, visual skin texture, and diaper dermatitis. Skin smoothness (tactile) and skin texture will be measured on a 10-point modified Griffith's scale, where 0 is the best possible condition and 9 is the worst possible condition, and diaper dermatitis will be measured on a 5-point scale, where 0 is the best possible condition and 4 is the worst possible condition. A decrease in scores indicates an improvement.
Secondary Outcomes
- Subject Satisfaction(Day 1, Week 1, Week 3)
- Product Tolerability(Week 1, Week 3)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 3
Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple SclerosisMultiple SclerosisNCT00370071Bayer39
Recruiting
Phase 3
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BHemophilia BHemophilia ANCT05611801Pfizer100
Recruiting
Early Phase 1
CS-206 in Patients With Sickle Cell DiseaseSickle Cell DiseaseNCT06565026CorrectSequence Therapeutics Co., Ltd5
Completed
Phase 2
Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment StudyHepatitis C Virus InfectionNCT02300103Gilead Sciences69
Completed
Phase 2
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.Non Small Cell Lung CancerNCT00160043Bayer112